Dose-response assessment of the anti-cancer efficacy of soy isoflavones in dimethylhydrazine-treated rats fed 6% fructooligosaccharide*

Hye-Young Sung and Young-Sun Choi§
Department of Food and Nutrition, Daegu University, Gyeongbuk 712-714, Korea

Received April 14, 2008; Revised May 7, 2008; Accepted May 19, 2008

Abstract
We investigated the combinatorial effects of different doses of dietary soy isoflavones (SI) and fructooligosaccharide (FOS) in a rat model of colon cancer. We hypothesized that increased bioavailability of SI metabolites due to dietary FOS may increase production of bioactive equol and affect colon carcinogenesis in a dose-dependent manner. Sprague-Dawley male rats were injected with 12-dimethylhydrazine (DMH) and were provided experimental diets that contained 0, 10, 50, 150, or 500 mg SI per kg of diet and 6% FOS for 12 weeks. The number of aberrant crypt foci (ACF) and the expression of cyclooxygenase-2 (COX-2) in colonic tissues were significantly decreased in the 6% FOS-fed groups compared to the control group. Gut transit time and fecal pH were significantly lower, and fecal concentrations of bifidobacteria were increased with 6% FOS. However, dietary SI supplementation in combination with 6% dietary FOS did not affect ACF formation or COX-2 expression. Plasma equol concentrations were dose-dependently increased by supplementation of SI up to 500 mg/kg of diet. In conclusion, SI supplementation up to 500 mg/kg of diet appeared to have no additive beneficial effects in rats with chemically-induced colon cancer that were fed 6% FOS, although plasma equol was dose-dependently increased.

Key Words: Aberrant crypt foci, cyclooxygenase-2, fructooligosaccharide, soy isoflavone, colon cancer

Introduction
Diet and behavior underlie the etiology of various types of cancer. Specifically, colon and rectal cancer occurrence is ten-fold higher in developed countries than in non-developed countries (WHO, 2003), and diet-related factors may account for up to 80% of this regional difference in cancer occurrence (Cummings & Bingham, 1998). Consumption of foods containing soy isoflavones (SI) such as genistein and daidzein has been weakly associated with reduced colon cancer risk (Cotterchio et al., 2006; Messina & Bennink, 1998). Dietary SI and estriol were shown to reduce colon tumorigenesis in azoxymethane-treated ovariectomized mice (Guo et al., 2004); however, the bioavailability of such isoflavones is influenced by their chemical form in foods, their hydrophobicity and susceptibility to degradation, the microbial flora of the consumer, and the food matrix (Birt et al., 2001). In particular, equol, a product derived from intestinal bacterial metabolism (Atkinson et al., 2004; Setchell et al., 2002), displays more estrogenic potency than its precursor isoflavone, daidzein (Atkinson et al., 2005). Nevertheless, the inter-relationships and effects of SI and colonic microflora on colon cancer are unclear.

Evidence from a wide range of sources supports the notion that colonic microflora are involved in the etiology of colon cancer (Lim et al., 2005; Onoue et al., 1997). Dietary fructooligosaccharide (FOS) improves the gut ecosystem by increasing bifidobacteria and dose-dependently shortens gut transit time in 1,2-dimethylhydrazine (DMH)-treated rats (Sung et al., 2006). Specifically, FOS alters the bioavailability of daidzein and genistein (Uehara et al., 2001) and inhibits the formation of aberrant crypt foci (ACF) (Pierre et al., 1997). In a previous study, we observed that FOS dose-dependently suppressed ACF formation and that supplementation of the diet with SI (1,000 mg/kg) resulted in an additional suppressive effect on colon carcinogenesis (Sung & Choi, 2008).

Therefore, we hypothesized that production of SI metabolites such as equol in the presence of FOS may increase the relative proportion of bioactive isoflavones and alter the expression of colon cancer biomarkers. Here we assessed the dose-response effectiveness of SI fed concomitantly with 6% FOS on ACF formation, cyclooxygenase-2 (COX-2) expression in colonic tissues, gut ecosystem, and plasma equol concentration in a rat model of colon cancer.

* This work was supported by Korea Research Foundation Grant funded by the Korean Government(MOEHRD; KRF-2005-F00084).
§ Corresponding Author: Young-Sun Choi, Tel. 82-53-850-6833, Fax. 82-53-850-6839, Email. yschoi@daegu.ac.kr
**Table 1. Experimental diet compositions (g/kg diet)**

| Ingredients          | Normal | Control | SI-0 | SI-10 | SI-50 | SI-150 | SI-500 |
|----------------------|--------|---------|------|-------|-------|--------|--------|
| Cornstarch           | 509.5  | 509.5   | 509.5| 509.45| 509.25| 508.75 | 507    |
| Casein               | 200    | 200     | 200  | 200   | 200   | 200    | 200    |
| Sucrose              | 120    | 120     | 60   | 60    | 60    | 60     | (10.30)| (10.30)| (10.30)| (10.30)| (10.30)| (10.30)|
| Soybean oil          | 70     | 70      | 70   | 70    | 70    | 70     | 70     |
| Fiber                | 50     | 50      | 50   | 50    | 50    | 50     | 50     |
| Mineral mix          | 35     | 35      | 35   | 35    | 35    | 35     | 35     |
| Vitamin mix          | 10     | 10      | 10   | 10    | 10    | 10     | 10     |
| L-Cystine            | 3      | 3       | 3    | 3     | 3     | 3      | 3      |
| Choline bitartrate   | 2.5    | 2.5     | 2.5  | 2.5   | 2.5   | 2.5    | 2.5    |
| Soy isoflavones      | 0      | 0       | 0    | 0.05  | 0.25  | 0.75   | 2.5    |
| Fructooligosaccharide| 0      | 0       | 0    | 0     | 0     | 0      | 0      |
| Total                | 1,000  | 1,000   | 1,000| 1,000 | 1,000 | 1,000  | 1,000  |

1) Sucrose and glucose contained in the fructooligosaccharide (FOS) syrup account for the difference (actual amount used shown in parentheses).
2) Amount of soy isoflavone powder containing 20.23% aglycone forms (daidzein 8.18%, glycitein 9.85%, and genistein 2.20%).
3) Fructooligosaccharide syrup (actual amount used shown in parentheses) was composed of 41% fructooligosaccharide, 25% water, glucose, and sucrose.

**Methods and Materials**

**Animals and diets**

Four week-old male Sprague Dawley rats (n = 70) were procured from Daehan Biolink Co. (Chungbuk, Korea) and were acclimated to the facility for 1 week. Water and standard rodent chow (Samyang Feed Co., Gangwon, Korea) were provided ad libitum. Rats (n=60) were injected subcutaneously twice per week for 4 weeks with DMH (20 mg/kg body weight) in ethylene-diaminetetraacetic acid (EDTA, 1 mM, pH 6.7) to induce colon cancer. Ten rats were injected with the equivalent volume of EDTA solution for use as normal rats. The DMH-injected rats were divided into six groups of ten rats each and were fed different experimental diets (Table 1) for 12 weeks.

The AIN93-based experimental diets (American Institute of Nutrition, 1993) contained 0, 10, 50, 150, or 500 mg of SI per kg of chow and were given concomitantly with 6% FOS. The Nutritional Tables (CJ Co., Seoul, Korea) contained 0, 10, 50, 150, or 500 mg of SI per kg of chow and were given concomitantly with 6% FOS. The AIN93-based experimental diets were configured using the AIN’93 protocol (American Institute of Nutrition, 1993). Water and standard rodent chow (Samyang Feed Co., Gangwon, Korea) were provided ad libitum. The rats were weighed twice per week. The protocols and use of rats were approved by the Animal Care and Use Committee of Daegu University (Gyeongsan, Korea).

**Measurement of fecal pH and gut transit time**

Fresh feces collected at week 12 of the experimental diet were diluted four times with distilled water, and a pH electrode (ORION model 420A; Thermo Electron Co., Waltham, MA, USA) that was completely immersed in the sample solution was used to measure the pH. The gut transit time was determined by measuring the time of the first appearance of carmine red in the feces following the addition of 0.5% carmine red to the diet.

**Measurement of plasma concentration of equol**

Plasma equol glucuronides and sulfates were hydrolyzed, and equol was extracted for time-resolved fluorescence (TR-FIA; Brouwers et al., 2003) using an equol kit (Labmaster Ltd, Turku, Finland). All reagents and samples were brought to room temperature (20-25°C) before use. All reagents were purchased from Wallac Oy (Turku, Finland), and the TR-FIA for equol was performed as follows. An aliquot of 200 μL of acetate buffer (0.1 M, pH 5.0, containing 0.2 U/mL of β-glucuronidase and 2 U/mL of sulfates) was added to tubes containing 200 μL of plasma. After mixing, the samples were incubated overnight at 37°C. The following day, the free equol was extracted with 1.5 mL diethyl ether by careful mixing of the two phases for 3 minutes. After thawing, the water phase was frozen in a dry ice-ethanol mixture, and the ether phase was re-extracted with ether in a disposable glass tube; the ether phases were combined and evaporated to dryness at 45°C in a water bath. Assay buffer (200 μL) was added to the tubes, and, after careful mixing, 20 μL of the solution corresponding to 20 μL of the original plasma sample were taken for TR-FIA. Its equol concentration was determined by a Victor 1420 multi-label counter with software version 2.0 for fluorescence measurements (Perkin Elmer Life and Analytical Sciences, Inc., Finland).

**Quantification of ACF**

Colons were removed, flushed with ice-cold saline, and slit open from the anus to the cecum on a cold plate. The distal...
Table 3. Effects of soy isoflavones (SI) and fructooligosaccharide (FOS) on fecal microflora of DMH-treated rats

| Group       | Bifidobacteria | Lactobacilli | Bacteroides | Total anaerobes | Total aerobes |
|-------------|----------------|--------------|-------------|----------------|--------------|
| Normal      | 5.798 ± 0.199a | 6.513 ± 0.161a | 6.766 ± 0.150a | 6.864 ± 0.123a | 6.962 ± 0.170a |
| Control     | 5.918 ± 0.157b | 6.560 ± 0.181b | 6.955 ± 0.269b | 7.052 ± 0.219b | 7.147 ± 0.307b |
| Control-FOS | 7.576 ± 0.175a | 7.106 ± 0.254a | 7.916 ± 0.218a | 8.122 ± 0.201a | 9.102 ± 0.422a |
| SI 10-FOS   | 7.473 ± 0.286a | 7.603 ± 0.342a | 8.355 ± 0.195a | 8.325 ± 0.134a | 8.205 ± 0.219a |
| SI 50-FOS   | 7.145 ± 0.246a | 7.423 ± 0.297a | 8.015 ± 0.217a | 8.398 ± 0.134a | 7.352 ± 0.351a |
| SI 150-FOS  | 7.036 ± 0.219a | 7.628 ± 0.283a | 8.247 ± 0.150a | 8.398 ± 0.134a | 7.352 ± 0.351a |
| SI 500-FOS  | 7.344 ± 0.238a | 7.724 ± 0.220a | 8.293 ± 0.153a | 8.222 ± 0.179a | 6.927 ± 0.344a |

DMH-treated rats were fed an experimental diet that contained 0, 10, 50, 150, or 500 mg/kg of diet SI with 6% FOS for 12 weeks. Normal and control rats were fed AIN-93 diet.

Values are mean ± SEM for n=10; *n=5 (2 rats pooled).

Statistical analysis

The results were expressed as means ± standard error of the mean (SEM). The SPSS release 15.0 software package (SPSS Inc., Chicago, IL, USA) was used for the statistical analyses. Differences of means between the groups that were significant at P < 0.05 using one-way analysis of variance (ANOVA) were tested by Duncan's multiple range tests at P < 0.05.
contents of SI in the experimental diet and from food intake. The intakes of total SI/kg body weight/day were 0.562, 2.821, 8.319, and 27.679 mg from diets containing 10, 50, 150, and 500 mg SI/kg of diet, respectively. The daily intake of SI per animal corresponded to 0.212, 1.073, 3.137, and 10.424 mg, respectively. Nevertheless, there were no significant differences among groups with increasing doses of SI (Table 2).

**Fecal pH, fecal microflora, and gut transit time**

After 12 weeks of feeding, fecal pH was significantly lower in rats fed 6% FOS diets than in rats from normal and control groups. Gut transit time was significantly reduced with FOS supplementation, except that containing 500 mg of SI, compared to the control diet (Fig. 1). However, SI supplementation did not affect fecal pH or gut transit time.

The dosage of SI did not affect the fecal microflora (Table 3). Fecal concentrations of bifidobacteria, lactobacilli, bacteroides, and total anaerobes were significantly increased by FOS in diets, except lactobacilli concentration of the control-FOS group which was not significantly different from that of the control group. However, total aerobe concentrations were not significantly different among the groups.

**Plasma equol concentration**

Plasma equol concentration was increased by SI in a dose-dependent manner up to 500 mg SI/kg diet (Fig. 2). The increase of plasma equol concentration at the dose of 10 mg SI/kg diet was insignificant compared to the control group. Concentrations of plasma equol were increased significantly with diets containing ≥50 mg SI/kg diet.

---

Fig. 1. Effects of different doses of soy isoflavones (SI) on fecal pH and gut transit time in DMH-treated rats fed a diet containing fructooligosaccharide (FOS). Rats were fed experimental diets that contained 0, 10, 50, 150, or 500 mg SI per kg diet and 6% FOS for 12 weeks. Data are mean ± SE values (n = 10). Means with different letters are significantly different from each other by Duncan’s multiple range test at p < 0.05.

Fig. 2. Effects of different doses of soy isoflavones (SI) and fructooligosaccharide (FOS) on plasma equol concentrations in DMH-treated rats. Rats were fed experimental diets that contained 0, 10, 50, 150, or 500 mg SI per kg diet and 6% FOS for 12 weeks. Data are mean ± SE values (n = 10). Means with different letters are significantly different from each other by Duncan’s multiple range test at p < 0.05.

Fig. 3. Effects of different doses of soy isoflavones (SI) and fructooligosaccharide (FOS) on numbers of (top) ACF and (bottom) ACF with four or more ACs per focus in the colons of DMH-treated rats. Rats were fed experimental diets that contained 0, 10, 50, 150, or 500 mg SI per kg diet and 6% FOS for 12 weeks. Data are mean ± SE values (n = 10). Means with different letters are significantly different from each other by Duncan’s multiple range test at p < 0.05.
The numbers of ACF and the numbers of ACF containing four or more crypts per focus were decreased significantly in rats fed FOS, regardless of the dose of SI, compared to control rats that were not fed FOS. SI at all doses did not affect the number of ACF in rats (Fig. 3).

The expression level of COX-2 in the colonic mucosa was increased significantly in the control rats compared to the normal rats. Expression of COX-2 was significantly decreased with the addition of 6% FOS to the diet. However, the COX-2 expression level was not significantly affected by the addition of SI to the diet (Fig. 4).

**Discussion**

We assessed whether dietary SI, given with 6% FOS, would affect the development of DMH-induced early lesions of colon cancer in rats. The FOS-supplemented diet lowered ACF formation as well as COX-2 expression in colonic tissues, and these results are in agreement with those of our previous study (Sung & Chioi, 2008). ACF are lesions in which more than two aberrant crypts are stuck together, and ACF with four or more AC per focus are reliable predictors of malignancy (Bird & Good, 2000; Onoue et al., 1997). Overexpression of COX-2 has also been observed in colon tumors (Sheehan et al., 1999); in animal studies, blocking COX-2 chemically or by mutation causes a marked decrease in colon cancer development (Jacoby et al., 2000; Oshima et al., 1996). Suppression of colon cancer biomarkers by 6% FOS in diets most likely occurred due to an improvement in the gut ecosystem. The FOS diet increased the proportion of bifidobacteria relative to total anaerobes, shortened gut transit time, and lowered gut pH. However, SI, even at high doses, did not affect the gut ecosystem or suppress biomarkers of colon cancer in rats.

Nielsen and Williamson (2007) summarized data from 16 studies on factors affecting the bioavailability of SI. According to their reports, the bioavailabilities of genistein and daidzein are increased by a rapid gut transit time and by low fecal digestion rates and are decreased by a fiber-rich diet; moreover, the summarized data suggest a reasonable correlation between the dose of SI and Cmax. In our study, feeding SI for 12 weeks resulted in a dose-dependent increase in the plasma equol concentration. The dose of 500 mg SI/kg diet corresponded to 27.68 mg SI/kg body weight. There are few reports dealing with association of dose of SI, plasma equol concentration, and health benefit of increased SI intake. According to Mathey et al. (2004), plasma equol concentrations increased dose-dependently with SI up to 80 mg/kg body weight in ovariectomized rats fed experimental diets for 90 days. Furthermore, SI exhibited a bone-sparing effect at 20 mg/kg body weight/day, and addition of FOS to the diet significantly increased SI protection of the skeleton. Other work by Khalil et al. (2005) showed that 600 mg and 1200 mg SI/kg diet resulted in a bone-sparing effect in orchidectomized aged male rats that were fed the experimental diets for 180 days. Collectively, these studies demonstrate that fairly high levels of SI (i.e., ≥20 mg/kg body weight) are required for beneficial effects on bone. Of these isoflavones, daidzein which is a direct precursor of equol appears to be more efficient for the prevention of bone loss than genistein as demonstrated by studies in castrated rats (Picherit et al., 2000).

The average intake of total SI/kg body weight/day estimated from the diet containing 500 mg SI/kg was 27.679 mg (11.192 mg daidzein and 2.955 mg genistein) in this study. The level is below NOAEL (no observed adverse effect level) of genistein, 50 mg/kg body weight/day estimated by McClain et al. (2006) who carried out hazard analyses for acute, subchronic and chronic safety of genistein in rats.

Several epidemiological studies suggest that isoflavones in soy may prevent the development of colon cancer in humans (Adlercreutz, 1995; Birt et al., 2001; Cotterchio et al., 2006). Consistently, our previous study showed an independent suppressive effect of SI (1,000 mg/kg of diet) on colon cancer biomarkers, and these effects of SI were also synergic with FOS. In contrast, Sorensen et al. (1998) reported that high amounts of SI (475 mg of total isoflavones per kg diet) in a Western-type high risk diet did not protect against intestinal tumor development in a relevant animal model such as Min mice. Furthermore, animal studies in general have not demonstrated an inhibitory effect by soy foods and isoflavones on the development of chemically-induced colorectal cancer (Messina & Bennink, 1998). In a recent study by Daly et al. (2007), dietary SI (2 g/kg diet) did not provide protection against the development of preneoplastic colonic ACF in female rats. However, Guo et al., (2004) reported that estrione and SI have been associated with
lower incidences of colon tumors.

Prebiotics such as FOS increase the intestinal bioavailability and affect the metabolism of isoflavones in rats (Uehara et al., 2001), and increase microbial production of equol in mice (Ohta et al., 2002). In our study, even relatively large doses of SI (up to 500 mg/kg diet) that increased plasma equol did not offer additional protection to that provided by FOS against colon carcinogenesis. These results indicate that equol production from SI is not directly related to an inhibitory effect on colon cancer. It is plausible, however, that a favorable ecosystem of hosts that was maintained by the presence of 6% dietary FOS may negate the suppressive effect of SI on biomarkers of colon cancer. Further studies are required to delineate a potential role for SI themselves in colorectal carcinogenesis.

Literature cited

Adlercreutz H (1995). Phytoestrogens: epidemiology and a possible role in cancer protection. Environ Health Perspect 103:103-112.

American Institute of Nutrition (1993). Report of the ad hoc committee on standards for nutrition studies. J Nutr 123:1939-1951.

Atkinson C, Berman S, Humbert O & Lampe JW (2004). In vitro incubation of human feces with daidzein and antibiotics suggests interindividual differences in the bacteria responsible for equol production. J Nutr 134:596-599.

Atkinson C, Frankenfeld CL & Lampe JW (2005). Gut bacterial metabolism of soy isoflavone daidzein: Exploring the relevance to human health. Exp Biol Med 230:155-170.

Bird RP (1995). Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett 93:55-71.

Bird RP & Good CK (2000). The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer. Toxicol Lett 112-113:395-402.

Birt DF, Hendrich S & Wang W (2001). Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol Ther 90:157-177.

Brouwers E, L’homme R, Al-Maharik N, Lapck O, Hampil R, Wahala K, Mikola H & Adlercreutz H (2003). Time-resolved fluorimunoassay for equol in plasma and urine. J Steroid Biochem Mol Biol 84:577-587.

Cho JW, Park K, Kweon GR, Jang BC, Baek WK, Suh MH, Kim CW, Lee KS & Suh SI (2005). Curcumin inhibits the expression of COX-2 in UVB-irradiated human keratinocytes (HaCaT) by inhibiting activation of AP-1: p38 MAP kinase and JNK as potential upstream targets. Exp Mol Med 37:186-192.

Cotterchio M, Boucher BA, Manno M, Gallinger S, Okey A & Harper P (2006). Dietary phytoestrogen intake is associated with reduced colorectal cancer risk. J Nutr 136:3046-3053.

Cummins JH & Bingham SA (1998). Diet and the prevention of cancer. BMJ 317:1636-1640.

Daly KT, Tracy AC, Malik M, Wang T, Francke-Carroll S & Magnuson BA (2007). Enhanced estrogenic responses and sensitivity to azoxymethane following dietary soy isoflavone supplementation in older female rats. Food Chem Toxicol 45:628-637.

Guo JY, Li X, Browning J, Rottinghaus GE, Lubahn DB, Constantinou A, Bennink M, & MacDonald R (2004). Dietary soy isoflavones and estrone protect ovariectomized ERαKO and wild-type mice from carcinogen-induced colon cancer. J Nutr 134:179-182.

Jacoby RF, Selbert K, Cole CE, Kelloff G & Lubet RA (2000). The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 60:5040-5044.

Ji GE, Kim IH, & Lee SK (1994). Investigation of selective medium for isolation and enumeration of Bacteroides sp. from the feces of the Korean people. Korean Journal of Food Science and Technology 26:295-299.

Khalil DA, Lucas EA, Smith BJ, Soung DY, Devareddy L, Juma S, Akhter MP, Recker AR & Arjmandi BH (2005). Soy isoflavones may protect against archidectomy-induced bone loss in aged male rats. Calcif Tissue Int 76:50-62.

Lim CC, Ferguson LR, & Tannock GW (2005). Dietary fibers as “prebiotics” : implications for colorectal cancer. Mol Nutr Food Res 49:609-619.

McClain RM, Wolzm E, Davidovish A, Pfannkuch F, Edwards JA, & Bausch J (2006). Acute, subchronic and chronic safety studies with genistein in rats. Food Chem Toxicol 44:56-80.

Matthey J, Puel S, Kati-Coulibaly S, Bennetau-Pelissero C, Daviocco MJ, Lebecque P, Horcajada MN & Coxam V (2004). Fructooligosaccharides maximize bone-sparing effects of soy isoflavone-enriched diet in the ovariectomized rat. Calcif Tissue Int 75:169-179.

Messina M & Bennink M (1998). Soyfoods, isoflavones and risk of colorectal cancer: a review of the in vitro and in vivo data. Baillieres Clin Endocrinol Metab 12:707-728.

Nielsen ILF & Williamson G (2007). Review of the factors affecting bioavailability of soy isoflavones in humans. Nutr Cancer 57:1-10.

Ohta, Uehara M, Sakai K, Takasaki M, Adlercreutz H, Morohoshi T & Ishimi Y (2002). A combination of dietary fructooligosaccharides and isoflavone conjugates increases femoral bone mineral density and equal production in ovariectomized mice. J Nutr 132:2048-2054.

Onoue M, Kado S, Sakaitani Y, Uchida K & Morotomi M (1997). Specific species of intestinal bacteria influence the induction of aberrant crypt foci by 1,2-dimethylhydrazine in rats. Cancer Lett 113:179-186.

Oshima M, Dinchuk JE, Kangman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JP & Taketo MM (1996). Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell 87:803-809.

Pichetrit C, Coxam V, Bennetau-Pelissero C, Kati-coulibaly S, Daviocco MJ, Lebecque P & Barlet JP (2000). Daidzein is more efficient than genistein in preventing ovariectomy-induced bone loss in rats. J Nutr 130:1675-1681.

Pierre F, Perrin P, Champ M, Bornet F, Meflah K & Menanteau J (1997). Short-chain fructo-oligosaccharides reduce the occurrence of colon tumors and develop gut-associated lymphoid tissue in Min mice. Cancer Res 57:225-228.

Sethchell KDR, Brown NM & Lydeking-Olsen E (2002). The clinical importance of the metabolite Equol - A clue to the effectiveness of soy and its isoflavones. J Nutr 132:3577-3584.

Sheehan KM, Sheehan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ & Murray FE (1999). The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 282:1254-1257.

Sorensen IK, Kristiansen E, Mortensen A, Nicolaisen GM, Wijnands JAH, van Kranen HJ, & van Kreijl CF (1998). The effect of soy
isoflavones on the development of intestinal neoplasia in Apc$^{Min}$ mouse. *Cancer Lett* 130:217-225.

Sung HY & Choi YS (2008). Fructooligosaccharide and soy isoflavone suppress colonic aberrant crypt foci and cyclooxygenase-2 expression in dimethylhydrazine-treated rats. *J Med Food* 11:78-85.

Sung HY, Lim YJ & Choi YS (2006). Soy isoflavones do not alter the effects of fructooligosaccharide on the intestinal ecosystem of colon-cancer model rats. *Food Sci Biotechnol* 15:931-936.

Uehara M, Ohta A, Sakai K, Suzuki K, Watanabe S & Adlercreutz H (2001). Dietary fructooligosaccharides modify intestinal bioavailability of a single dose of genistein and daidzein and affect their urinary excretion and kinetics in blood of rats. *J Nutr* 131:787-795.

WHO (2003). Technical Report Series 916, *Diet, Nutrition and the Prevention of Chronic Diseases*. pp.95-104, World Health Organization, Geneva, Switzerland